8-K: Elicio's ELI-002 Pancreatic Cancer Trial Advances

Elicio Therapeutics' ELI-002 7P Phase 2 study for mutant KRAS-driven pancreatic cancer received a positive Independent Data Monitoring Committee recommendation to continue without modifications, indicating preliminary efficacy signals.

Summary

• An Independent Data Monitoring Committee (IDMC) recommended continuing the Phase 2 AMPLIFY-7P study of ELI-002 7P in mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC) without modifications.
• The IDMC confirmed the favorable safety profile of ELI-002 7P to date.
• The company believes the IDMC's positive recommendation indicates that ELI-002 7P has shown preliminary signals of efficacy.
• Final disease-free survival (DFS) analysis for the AMPLIFY-7P study is anticipated to occur in the fourth quarter of 2025.
• Elicio previously reached alignment with the U.S. Food and Drug Administration (FDA) on key elements of the planned pivotal Phase 3 study design.
• The AMPLIFY-7P trial is a 2:1 randomized, open-label, multicenter clinical trial that enrolled 144 patients at 24 U.S. sites.
• The study evaluates the effectiveness and safety of ELI-002 7P monotherapy compared to standard of care (observation) to improve DFS in patients with PDAC in the adjuvant setting post local therapy.
• ELI-002 7P is an investigational, off-the-shelf immunotherapy vaccine targeting seven KRAS mutations found in 88% of PDAC patients and 25% of all solid tumors.
• The company remains blinded to the trial's clinical efficacy outcomes.
• The company's current cash runway extends into the first quarter of 2026, past the anticipated final DFS analysis.

Sentiment

Score: 8

Explanation: The positive IDMC recommendation to continue the trial without modifications, coupled with a favorable safety profile and alignment with the FDA on Phase 3 design, indicates strong progress for a high-need indication. The cash runway extending beyond the next key data readout is also positive. The primary uncertainty is the unblinded efficacy data, which is not yet public.

Positives

• The Independent Data Monitoring Committee (IDMC) recommended continuing the Phase 2 AMPLIFY-7P study without modifications, which the company views as an indication of preliminary efficacy signals.
• The IDMC confirmed a favorable safety profile for ELI-002 7P.
• Elicio previously reached alignment with the FDA on key elements of the planned pivotal Phase 3 study design.
• The company's current cash runway extends into Q1 2026, which is past the anticipated final DFS analysis in Q4 2025, providing financial stability for the next key milestone.
• ELI-002 7P targets seven common KRAS mutations, covering a significant patient population (88% of PDAC patients and 25% of all solid tumors).
• The off-the-shelf vaccine approach offers potential benefits of low cost, rapid commercial scale manufacturing, and rapid availability of the drug to patients.

Negatives

• Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a five-year survival rate of 13%.
• PDAC is projected to become the second leading cause of cancer death in the U.S. by 2030, highlighting the severity of the disease.
• The company remains blinded to the trial's clinical efficacy outcomes, meaning the 'preliminary signals of efficacy' are an interpretation of the IDMC's decision to continue, not direct efficacy data.

Risks

• Elicio's financial condition, including its anticipated cash runway, and its ability to obtain the necessary funding to advance the development of ELI-002 and any other future product candidates.
• The company's ability to continue as a going concern.
• The timing of initiation of Elicio's planned clinical trials.
• The timing of the availability of data from Elicio's clinical trials, including the final DFS analysis from the Phase 2 AMPLIFY-7P trial expected in the fourth quarter of 2025.
• The timing of any planned investigational new drug application or new drug application.
• Actual results may differ materially from forward-looking statements due to various factors.
• New factors may emerge from time to time that could impact the business or cause actual results to differ materially from those contained in any forward-looking statements.

Future Outlook

Elicio plans to request an End-of-Phase 2 meeting with the FDA to finalize the regulatory strategy for the ELI-002 Phase 3 study upon final DFS analysis in Q4 2025. The company also intends to expand ELI-002 to other indications, including mKRAS-positive lung cancer and other mKRAS-positive cancers, and potentially in combination regimens for PDAC and colorectal cancer.

Management Comments

• "We are encouraged by the IDMC’s recommendation to support the continuation of the AMPLIFY-7P trial as planned, as we believe it indicates that ELI-002 7P has shown preliminary signals of efficacy." Robert Connelly, Chief Executive Officer of Elicio.
• "We look forward to the final disease-free survival (DFS) analysis anticipated to occur in the fourth quarter of 2025 and continue to believe that ELI-002 7P has the potential, based on the compelling data generated to date, to offer a new solution to patients facing PDAC in the adjuvant setting." Robert Connelly, Chief Executive Officer of Elicio.

Industry Context

The announcement highlights significant progress in the challenging field of pancreatic cancer treatment, an aggressive cancer with a low 5-year survival rate (13%) and projected to be the second leading cause of cancer death by 2030. Elicio's focus on mKRAS mutations aligns with a critical target in oncology, as these mutations drive approximately 25% of all solid tumors. The company's 'off-the-shelf' vaccine approach contrasts with personalized vaccines, offering potential benefits in cost, manufacturing, and rapid availability, which could be a significant advantage in the broader cancer vaccine landscape.

Comparison to Industry Standards

• The 5-year survival rate for pancreatic ductal adenocarcinoma (PDAC) is 13%, underscoring the high unmet medical need that ELI-002 7P aims to address.
• ELI-002 7P targets seven KRAS mutations, which are present in 88% of PDAC patients and 25% of all solid tumors, indicating a broad potential patient population compared to therapies targeting fewer mutations.
• The company's 'off-the-shelf' vaccine approach is presented as having potential benefits (low cost, rapid manufacturing, rapid availability) compared to personalized vaccine approaches, which are typically more complex and costly.
• Previous Phase 1 AMPLIFY-201 data for PDAC and colorectal cancer (CRC) showed a 16.3-month median recurrence-free survival and 28.9-month median overall survival for the full study population, providing a benchmark for the drug's performance in earlier stages.

Stakeholder Impact

• Shareholders: Positive news regarding clinical trial progression and regulatory alignment could increase investor confidence and potentially share price.
• Patients: Potential for a new, effective 'off-the-shelf' treatment option for a highly aggressive cancer (PDAC) with high unmet medical need.
• Employees: Continued progress in clinical development provides stability and validates ongoing research efforts.
• Regulatory Authorities: FDA alignment indicates a clear path forward for potential approval.

Next Steps

• Final disease-free survival (DFS) analysis for the AMPLIFY-7P study anticipated in Q4 2025.
• Request an End-of-Phase 2 meeting with the FDA to finalize the regulatory strategy for the ELI-002 Phase 3 study upon final DFS analysis.
• Future expansion of ELI-002 to other indications, including mKRAS-positive lung cancer and other mKRAS-positive cancers.
• Potential future development of ELI-002 in combination regimens for PDAC and colorectal cancer.

Key Dates

Recommendation

The positive IDMC recommendation to continue the Phase 2 trial without modifications, coupled with a favorable safety profile and prior FDA alignment on Phase 3 design, significantly de-risks the ELI-002 program for a high-unmet-need indication like pancreatic cancer. The cash runway extends beyond the next major data readout, providing financial stability. While efficacy data remains blinded, the IDMC's decision strongly suggests positive preliminary signals. This progress positions Elicio for a pivotal Phase 3 study, representing a major milestone for a clinical-stage biotech.

Keywords

Elicio Therapeutics, ELTX, ELI-002, AMPLIFY-7P, pancreatic cancer, PDAC, KRAS, immunotherapy, cancer vaccine, clinical trial, Phase 2, oncology, biotechnology, drug development, FDA, IDMC, disease-free survival